Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: A novel epigenetic-targeting approach in acute myeloid leukemia

Histone deacetylase (HDAC) inhibitors either alone or in combination with hypomethylating agents have limited clinical effect in acute myeloid leukemia (AML). Previously we demonstrated that AML patients with higher miR-29b expression had better response to the hypomethylating agent decitabine. Ther...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Mims, Alice, Walker, Alison R., Huang, Xiaomeng, Sun, Jin, Wang, Hongyan, Santhanam, Ramasamy, Dorrance, Adrienne M., Walker, Chris, Hoellerbauer, Pia, Tarighat, Somayeh S., Chan, Kenneth K., Klisovic, Rebecca B., Perrotti, Danilo, Caligiuri, Michael A., Byrd, John C., Chen, Ching-Shih, Lee, L. James, Jacob, Samson, Mrózek, Krzysztof, Bloomfield, Clara D., Blum, William, Garzon, Ramiro, Schwind, Sebastian, Marcucci, Guido
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3764604/
https://ncbi.nlm.nih.gov/pubmed/23178755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2012.342
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars